Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single‑institutional experiences

Wolny‑Rokicka,Edyta; Sutkowski,Krzysztof; Grządziel,Aleksandra; Dorsz,Żaneta; Tukiendorf,Andrzej; Lipiński,Jakub; Wydmański,Jerzy

doi:10.3892/mco.2016.851

Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single‑institutional experiences

Authors:
- Edyta Wolny‑Rokicka
- Krzysztof Sutkowski
- Aleksandra Grządziel
- Żaneta Dorsz
- Andrzej Tukiendorf
- Jakub Lipiński
- Jerzy Wydmański
View Affiliations

Affiliations: Department of Radiotherapy, Lubuski Center of Oncology, Regional Hospital in Zielona Góra, 65‑001 Zielona Góra, Poland, First Department and Clinic of General, Gastroenterological and Endocrinological Surgery, Wrocław Medical University, 50‑369 Wrocław, Poland, Department of Medical Physics, Center of Oncology, Maria Sklodowska‑Curie Memorial Institute, Gliwice Branch, 44‑101 Gliwice, Poland, Department of Radiotherapy, Center of Oncology, Maria Sklodowska‑Curie Memorial Institute, Gliwice Branch, 44‑101 Gliwice, Poland, Department of Epidemiology and Silesia Cancer Registry, Center of Oncology, Maria Sklodowska‑Curie Memorial Institute, Gliwice Branch, 44‑101 Gliwice, Poland, University of Zielona Góra, Faculty of Computer, Electrical and Control Engineering, 65‑001 Zielona Góra, Poland
Published online on: April 7, 2016 https://doi.org/10.3892/mco.2016.851
Pages: 1088-1092

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to investigate hypofractionated radiotherapy (RT) in patients with locally advanced or metastatic adenocarcinoma of the pancreas. A total of 31 patients were enrolled in this study, 26 of whom had locally advanced (M0) pancreatic cancer and 5 had metastatic (M1) disease. The patients were treated with palliative RT (6‑30 Gy in 1‑10 fractions over a period of 1 day‑2 weeks). Treatment‑related toxicity was classified according to the Common Terminology Criteria for Adverse Events, version 3.0. Early mild toxicity was observed. A total of 17 patients (55%) achieved good pain control without pharmacological therapy, and 12 patients (39%) reduced their use of analgesics; in the remaining 2 patients (6%), there was no change in analgesic use. Late high‑grade (>3) toxicity was not observed. The average survival time for the 31 patients was 9 months. The 1‑year overall survival rate was 16%. Palliative RT was well-tolerated and was able to prolong the survival time. The majority of the patients achieved better pain control with palliative RT.

View Figures

View References

1	Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol. 29(Suppl 9): 23–31. 2002. View Article : Google Scholar : PubMed/NCBI
2	Goggins M: Molecular markers of early pancreatic cancer. J Clin Oncol. 23:4524–4531. 2005. View Article : Google Scholar : PubMed/NCBI
3	Chua YJ and Cunningham D: Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol. 23:4532–4537. 2005. View Article : Google Scholar : PubMed/NCBI
4	Real FX: A ‘catastrophic hypothesis’ for pancreas cancer progression. Gastroenterology. 124:1958–1964. 2003. View Article : Google Scholar : PubMed/NCBI
5	Nitecki SS, Sarr MG, Colby TV and van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 221:59–66. 1995. View Article : Google Scholar : PubMed/NCBI
6	Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg. 4:567–579. 2000. View Article : Google Scholar : PubMed/NCBI
7	Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP and Talamonti MS: Multimodality therapy for pancreatic cancer in the U.S.: Utilization, outcomes, and the effect of hospital volume. Cancer. 110:1227–1234. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sener SF, Fremgen A, Menck HR and Winchester DP: Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 189:1–7. 1999. View Article : Google Scholar : PubMed/NCBI
9	Crane CH, Evans DB, Wolff RA, Abbruzzese JL, Pisters PWT and Janjan NA: The pancreas. Radiation oncology: rationale, technique, results (8th). Cox J and Ang KK: (Mosby, St Louis, MO). 456–480. 2003.
10	Mantell BS: Radiotherapy for dysphagia due to gastric carcinoma. Br J Surg. 69:69–70. 1982. View Article : Google Scholar : PubMed/NCBI
11	Myint AS: The role of radiotherapy in the palliative treatment of gastrointestinal cancer. Eur J Gastroenterol Hepatol. 12:381–390. 2000. View Article : Google Scholar : PubMed/NCBI
12	Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: Digestive system. AJCC Cancer Staging Manual (6th). (Chicago, IL). Springer. 151–157. 2002.
13	Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events. version 3.0. DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed. August 09–2006
14	Krzyzanowska MK, Weeks JC and Earle CC: Treatment of locally advanced pancreatic cancer in the real word: population-based practices and effectiveness. J Clin Oncol. 21:3409–3414. 2003. View Article : Google Scholar : PubMed/NCBI
15	Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ and Lee SH: Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol. 42:86–91. 2008. View Article : Google Scholar : PubMed/NCBI
16	Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, et al: Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract Radiat Oncol. 2:77–85. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wild AT, Ye X, Ellsworth SG, et al: The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 38:259–265. 2015. View Article : Google Scholar : PubMed/NCBI
18	Morganti AG, Trodella L, Valentini V, Barbi S, Macchia G, Mantini G, Turriziani A and Cellini N: Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care. 19:258–262. 2003.PubMed/NCBI
19	Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA and Sauter PK: Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg. 217:447–457. 1993. View Article : Google Scholar : PubMed/NCBI
20	Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Mantilla CB and Warner DO: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA. 291:1092–1099. 2004. View Article : Google Scholar : PubMed/NCBI
21	Levy MJ and Wiersema MJ: EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc. 57:923–930. 2003. View Article : Google Scholar : PubMed/NCBI
22	Huguet F, Goodman KA, Azria D, Racadot S and Abrams RA: Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys. 83:1355–1364. 2012. View Article : Google Scholar : PubMed/NCBI
23	Goyal K, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, et al: Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res. 174:319–325. 2012. View Article : Google Scholar : PubMed/NCBI
24	Cascinu S, Falconi M, Valentini V and Jelic S: ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): v55–v58. 2010. View Article : Google Scholar : PubMed/NCBI
25	Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N and Nishimura T: Palliative radiotherapy for bleeding from advanced gastric cancer: Is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 137:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L and Crane CH: Pancreatic Tumor Study Group: Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 28:227–233. 2005. View Article : Google Scholar : PubMed/NCBI
27	Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI
28	Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 36:382–389. 2013. View Article : Google Scholar : PubMed/NCBI